Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 13 Aug 2022
FDA approves first NGS based companion diagnostic to aid in selecting non-small-cell lung cancer patients with HER2 (ERBB2) activating mutations (SNVs & exon 20 insertions) for treatment with Enhertu
12 August 2022 - This approval marks the Oncomine Dx Target Test’s eighth companion diagnostic therapy selection indication ...
Posted by Michael Wonder on 12 Aug 2022
NICE publishes first draft guidance from its Early Value Assessment pilot project recommending smartphone linked ECG device
12 August 2022 - It is the first recommendation to be issued by NICE’s diagnostics advisory committee via its Early Value ...
Posted by Michael Wonder on 12 Aug 2022
Dismay as UK ‘drags its heels’ on AZ’s COVID antibody Evusheld
12 August 2022 - Half a million people in the UK with conditions like blood cancer that prevents them being ...
Posted by Michael Wonder on 12 Aug 2022
US move to negotiate drug prices a rare defeat for big pharma
12 August 2022 - Big pharma spent more than any other industry to lobby Congress and federal agencies this year, ...
Posted by Michael Wonder on 12 Aug 2022
NICE recommendation expands patient eligibility for AbbVie’s Ozurdex
12 August 2022 - Treatment becomes an option for treating visual impairment caused by diabetic macular oedema, regardless of lens ...
Posted by Michael Wonder on 12 Aug 2022
For the second time, Pfizer tries a warranty in response to concerns over high drug costs
8 August 2022 - For only the second time, Pfizer is offering a warranty for a medicine that will cover ...
Posted by Michael Wonder on 12 Aug 2022
2022-2023 cost recovery implementation statement
12 August 2022 - The 2022-23 PBS and NIP cost recovery implementation statement is now available. ...
Posted by Michael Wonder on 12 Aug 2022
Enhertu approved in the U.S. as the first HER2 directed therapy for patients with previously treated HER2 mutant metastatic non-small-cell lung cancer
12 August 2022 - Based on DESTINY-Lung02 results which showed Daiichi Sankyo and AstraZeneca’s Enhertu reported a confirmed objective response ...
Posted by Michael Wonder on 11 Aug 2022
Lynparza receives Health Canada approval as adjuvant treatment for patients with germline BRCA mutated HER2 negative high-risk early breast cancer
11 August 2022 - First and only approved medicine targeting germline BRCA mutations in high-risk early breast cancer. ...
Posted by Michael Wonder on 11 Aug 2022
NICE lung cancer treatment pathways
11 August 2022 - As part of our commitment to identifying transformational care for the benefit of patients, NICE has ...
Posted by Michael Wonder on 11 Aug 2022
COVID-19 vaccine safety report (11 August 2022)
11 August 2022 - To 7 August 2022, the TGA has received 665 reports which have been assessed as likely to ...
Posted by Michael Wonder on 11 Aug 2022
FDA approves capmatinib for metastatic non-small-cell lung cancer
11 August 2022 - On August 10, 2022, the FDA granted regular approval to capmatinib (Tabrecta, Novartis) for adult patients ...
Posted by Michael Wonder on 11 Aug 2022
SMC approve Johnson & Johnson’s systemic light chain amyloidosis therapy
10 August 2022 - Newly diagnosed patients will become the first to access systemic light chain amyloidosis treatment in the ...
Posted by Michael Wonder on 11 Aug 2022
MHRA grants marketing authorisation for Novartis’ radioligand therapy Pluvicto (lutetium (Lu 177) vipivotide tetraxetan) in advanced prostate cancer in Great Britain
11 August 2022 - Locamet (gozetotide), a PSMA targeted positron emission tomography imaging tracer, has also received a licence from the ...
Posted by Michael Wonder on 11 Aug 2022
aTyr Pharma receives FDA fast track designation for efzofitimod (ATYR1923) for treatment of pulmonary sarcoidosis
11 August 2022 - Company is investigating efzofitimod in global pivotal Phase 3 EFZO-FIT study in pulmonary sarcoidosis patients. ...